TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28625655

Group type: EXPERIMENTAL
Intervention: Talc pleurodesis (TP)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Indwelling pleural catheter (IPC)
Number of subjects: 61
Study: 26525477

Group type: EXPERIMENTAL
Intervention: Furasol sore throat gargle solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Antibacterial therapy
Number of subjects: 40
Study: 21905162

Group type: EXPERIMENTAL
Intervention: GBOT group intervention (n = 216)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Usual care (CRL group, n = 226)
Number of subjects: 442
Study: 21262884

Group type: EXPERIMENTAL
Intervention: recombinant human prolactin (r‐hPRL)
Number of subjects: 11
Study: 18055921

Group type: EXPERIMENTAL
Intervention: Active capacitively coupled electric field stimulation applied for 15 hours per day until healed; supplemental calcium provided.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo capacitively coupled electric field stimulation applied for 15 hours per day until healed; supplemental calcium provided.
Number of subjects: 44
Study: 16481919

Group type: EXPERIMENTAL
Intervention: iomeprol 400 (400 mg iodine/mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: iopromide 370 (370 mg iodine/mL)
Number of subjects: 40
Study: 12590014

Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/day)
Number of subjects: 27
Study: 10630797

Group type: EXPERIMENTAL
Intervention: Reamed femoral nailing
Number of subjects: 170

Group type: COMPARATOR
Intervention: Unreamed femoral nailing
Number of subjects: 170
Study: 9106695

Group type: EXPERIMENTAL
Intervention: UC patients without PSC
Number of subjects: 87

Group type: COMPARATOR
Intervention: UC patients with PSC
Number of subjects: 87
Study: 8261677

Group type: EXPERIMENTAL
Intervention: Protein intake (g/kg/day)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Difference between protein-N intake and urea-N excretion
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Correlation of protein intake and urea-N excretion
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Maroni's formula
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Dietary diaries
Number of subjects: 123
Study: 3513667

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (60 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline pretreatment (control)
Number of subjects: 10
Study: 30314294

Group type: EXPERIMENTAL
Intervention: Pictorial health warning labels (HWLs) from Set A
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: Pictorial health warning labels (HWLs) from Set B
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Text-only health warning labels
Number of subjects: 1163
Study: 26857646

Group type: EXPERIMENTAL
Intervention: TDRD1 mRNA levels
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: TMPRSS2-ERG mRNA presence
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: TDRD1 mRNA level
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: TMPRSS2-ERG expression
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of mRNA expression of 11 candidate genes combined with KLK3, serum PSA, percentage-free PSA, and prostate volume
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Serum PSA, percentage-free PSA, and prostate volume
Number of subjects: 99
Study: 24291239

Group type: EXPERIMENTAL
Intervention: 24 weeks pegylated interferon and ribavirin
Number of subjects: 136

Group type: COMPARATOR
Intervention: 48 weeks pegylated interferon and ribavirin
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 24 weeks pegylated interferon and ribavirin (in patients with biopsy proven cirrhosis)
Number of subjects: 136

Group type: COMPARATOR
Intervention: 48 weeks pegylated interferon and ribavirin (in patients with biopsy proven cirrhosis)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 24 weeks pegylated interferon and ribavirin (in patients with cirrhosis proven on imaging)
Number of subjects: 136

Group type: COMPARATOR
Intervention: 48 weeks pegylated interferon and ribavirin (in patients with cirrhosis proven on imaging)
Number of subjects: 136
Study: 23041995

Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 40
Study: 20390593

Group type: EXPERIMENTAL
Intervention: Saccharide supplementation (3.6 g per day, taken as a teaspoon twice daily for 12 weeks)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 109
Study: 17456665

Group type: EXPERIMENTAL
Intervention: BIS-guided total IV anesthesia with propofol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Clinically guided total IV anesthesia with propofol
Number of subjects: 44
Study: 16134993

Group type: EXPERIMENTAL
Intervention: Fel d 1 peptides (approximately 300 mug in increasing, divided doses)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fel d 1 peptides (in open study)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12218725

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE, 0.625 mg daily) for 3 months, followed by CEE combined with low-dose medroxyprogesterone acetate (MPA, 2.5 mg daily) for an additional 3 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 38
Study: 10099941

Group type: EXPERIMENTAL
Intervention: Gaio (200 g daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7557852

Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 85
Study: 2112338

Group type: COMPARATOR
Intervention: 10 mg nitroglycerin (NTG) patch
Number of subjects: 30
Study: 213081

Group type: EXPERIMENTAL
Intervention: beta-sitosterol
Number of subjects: 15
Study: 30957868

Group type: EXPERIMENTAL
Intervention: Recognition of the spectral nature of heart failure and its implications for future trial designs.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathophysiological reasoning against the classification of HF based solely on LVEF.
Number of subjects: 0
Study: 29021121

Group type: EXPERIMENTAL
Intervention: TAU + CBT4CBT
Number of subjects: 71

Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 71
Study: 26418918

Group type: EXPERIMENTAL
Intervention: CPP‐ACFP (Mi Paste Plus)
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: CPP‐ACP (GC Tooth Mouse)
Number of subjects: 786

Group type: COMPARATOR
Intervention: Fluoride varnish (Duraphat)
Number of subjects: 786
Study: 23257248

Group type: EXPERIMENTAL
Intervention: Degarelix (240/80 mg monthly for 12 weeks)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Goserelin (3.6 mg monthly for 12 weeks) plus Bicalutamide (50 mg for 17 days initially)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 244

Group type: COMPARATOR
Intervention: Goserelin plus Bicalutamide
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Degarelix (in patients with baseline International Prostate Symptom Score ≥13)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Goserelin plus Bicalutamide (in patients with baseline International Prostate Symptom Score ≥13)
Number of subjects: 244
Study: 21288121

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) dosed twice daily (BID)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Atomoxetine (ATX) dosed once daily (QD)
Number of subjects: 55
Study: 19746679

Group type: EXPERIMENTAL
Intervention: 4% hydroquinone/0.05% tretinoin skin care system + IPL
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo + IPL
Number of subjects: 36
Study: 17941029

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy followed by prostatectomy
Number of subjects: 0
Study: 15088884

Group type: COMPARATOR
Intervention: Low-dose flurbiprofen (LDF) alone, 50 mg q.d.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Subantimicrobial dose doxycycline (SDD) alone, 20 mg b.i.d.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination of SDD plus LDF
Number of subjects: 19
Study: 11235927

Group type: EXPERIMENTAL
Intervention: Melatonin (5.4 mg mean stable dose)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 10193290

Group type: EXPERIMENTAL
Intervention: Neostigmine 2.0 mg and glycopyrrolate 0.4 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study: 8091148

Group type: EXPERIMENTAL
Intervention: Continuous oral pamidronate (APD), 1000 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 2897764

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29544550

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No IPC (control)
Number of subjects: 0
Study: 26980346

Group type: EXPERIMENTAL
Intervention: Warm temperature (31°C) during fasting and exercise sessions
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Warm temperature (31°C) during oral glucose tolerance tests (OGTTs)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Warm temperature (31°C) during OGTTs
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control temperature (22°C) during fasting and exercise sessions
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control temperature (22°C) during OGTTs
Number of subjects: 22
Study: 25765705

Group type: EXPERIMENTAL
Intervention: RM1 (≥3 days and/or nights of cough, wheeze, and/or medicine use) documented by parental diaries at 12 months corrected age
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: RM2 (≥4 days and/or nights of cough, wheeze, and/or respiratory medicine use) documented by parental diaries at 12 months corrected age
Number of subjects: 303

Group type: COMPARATOR
Intervention: BPD28d
Number of subjects: 303

Group type: COMPARATOR
Intervention: BPD36w
Number of subjects: 303
Study: 24385635

Group type: EXPERIMENTAL
Intervention: Everyday cognition
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Lower cognitive performance
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 698
Study: 20873879

Group type: EXPERIMENTAL
Intervention: Oxycodone (15 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18465717

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) sedation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (0.9% saline infusion)
Number of subjects: 44
Study: 16470429

Group type: EXPERIMENTAL
Intervention: All-polyethylene (AP) tibial component
Number of subjects: 39

Group type: COMPARATOR
Intervention: Metal-backed (MB) tibial component
Number of subjects: 39
Study: 12208482

Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin (40 mg/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 58
Study: 10596735

Group type: EXPERIMENTAL
Intervention: Bupropion SR (150-400 mg/day)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 364

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Bupropion SR and Sertraline
Number of subjects: 364
Study: 8740031

Group type: EXPERIMENTAL
Intervention: Partial resection (elective)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Partial resection (necessary)
Number of subjects: 28
Study: 1858760

Group type: EXPERIMENTAL
Intervention: Automated cardiovascular monitoring
Number of subjects: 618

Group type: COMPARATOR
Intervention: Clinical observation (Control)
Number of subjects: 618
Study: 6134979

Group type: EXPERIMENTAL
Intervention: 20 mg/day omeprazole
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 60 mg/day omeprazole
Number of subjects: 32
Study: 31402136

Group type: EXPERIMENTAL
Intervention: Complex multifaceted intervention consisting of repeated interdisciplinary case conferences (ICCs) involving general practitioners, pharmacists, and nurses, supported by a blended training program and local interdisciplinary meetings.
Number of subjects: 1804

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1804
Study: 30054154

Group type: EXPERIMENTAL
Intervention: Snacking at mid-afternoon (1530h)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Snacking just after lunch (1230h)
Number of subjects: 17
Study: 27184789

Group type: EXPERIMENTAL
Intervention: Inpatient psychodynamic treatment
Number of subjects: 46
Study: 24576541

Group type: EXPERIMENTAL
Intervention: Statin therapy at discharge
Number of subjects: 3512

Group type: COMPARATOR
Intervention: No statin therapy at discharge
Number of subjects: 3512
Study: 22733948

Group type: EXPERIMENTAL
Intervention: One-dose TEA group (10 mg/kg intra-operatively)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Two-dose TEA group (10 mg/kg pre-operatively and intra-operatively)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 151
Study: 21246575

Group type: EXPERIMENTAL
Intervention: Quantitative reflectance/fluorescence spectroscopic technique
Number of subjects: 40
Study: 18274163

Group type: EXPERIMENTAL
Intervention: Weekly nutrition education based on the nutrition triangle concept of UNICEF for 6 months
Number of subjects: 605

Group type: COMPARATOR
Intervention: Regular BINP services
Number of subjects: 605
Study: 16430563

Group type: EXPERIMENTAL
Intervention: TDS beta
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 14530690

Group type: EXPERIMENTAL
Intervention: Degassed aqueous solution made of 40 ml of water and 10 ml of dimethicone emulsion (1 ml/100 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional degassed water
Number of subjects: 100
Study: 10739631

Group type: EXPERIMENTAL
Intervention: Dementia with Lewy bodies (DLB)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Postmortem examination of brains
Number of subjects: 28
Study: 9124547

Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 1406817

Group type: EXPERIMENTAL
Intervention: Tacrine (10 or 20 mg four times a day)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Tacrine
Number of subjects: 215
Study: 6428371

Group type: EXPERIMENTAL
Intervention: Haloperidol (1.0 to 6.0 mg/day)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (500 to 2,000 mg/day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 30630891

Group type: EXPERIMENTAL
Intervention: CHEST intervention (consultation to discuss and implement a self-help manual, followed by self-monitoring reminders)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Control group (brief discussion about lung health)
Number of subjects: 551
Study: 29939063

Group type: EXPERIMENTAL
Intervention: Angry male attorney
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Angry female attorney
Number of subjects: 120

Group type: COMPARATOR
Intervention: Calm female attorney
Number of subjects: 120

Group type: COMPARATOR
Intervention: Calm male attorney
Number of subjects: 120
Study: 25946311

Group type: EXPERIMENTAL
Intervention: Nurse practitioner support
Number of subjects: 10

Group type: COMPARATOR
Intervention: Physician care alone
Number of subjects: 10
Study: 24641941

Group type: EXPERIMENTAL
Intervention: Olokizumab (OKZ) 60 mg
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Olokizumab (OKZ) 120 mg
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Olokizumab (OKZ) 240 mg
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Olokizumab (OKZ)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg Q4W
Number of subjects: 221
Study: 22522225

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (400mg and 100mg respectively) administered after a moderate-fat breakfast
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Coprandial administration of formulations
Number of subjects: 16
Study: 19693550

Group type: EXPERIMENTAL
Intervention: Paper point full length (FP) sampling
Number of subjects: 20

Group type: COMPARATOR
Intervention: Paper point half length (HP) sampling
Number of subjects: 20
Study: 17959861

Group type: EXPERIMENTAL
Intervention: Salsalate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15767505

Group type: EXPERIMENTAL
Intervention: Aspirin plus extended-release dipyridamole
Number of subjects: 3299

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 3299
Study: 12389758

Group type: EXPERIMENTAL
Intervention: Risk information presented in terms of relative risk reduction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Risk information presented in terms of absolute risk reduction or number needed to treat
Number of subjects: 100
Study: 10613628

Group type: EXPERIMENTAL
Intervention: Graded workload treadmill protocol (G-test; 2 mph; 0% grade, increasing 2% every 2 min)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Graded workload treadmill protocol (G-test)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Constant workload treadmill protocol (C-test; 2 mph; 12% grade)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Constant workload treadmill protocol (C-test)
Number of subjects: 330
Study: 7866799

Group type: EXPERIMENTAL
Intervention: TorTourn (ketorolac tromethamine at tourniquet inflation)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: TorEnd (ketorolac tromethamine at the end of surgery)
Number of subjects: 64

Group type: COMPARATOR
Intervention: TorNone (no ketorolac tromethamine)
Number of subjects: 64
Study: 2015162

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg three times daily for 10 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ibuprofen (600 mg three times daily for 10 days)
Number of subjects: 18
Study: 7159883

Group type: EXPERIMENTAL
Intervention: procainamide 1.0 g t.i.d.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: disopyramide 150 mg t.i.d.
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 31791332

Group type: EXPERIMENTAL
Intervention: PPF-permethrin nets (Olyset Duo)
Number of subjects: 1299

Group type: COMPARATOR
Intervention: Standard LLINs (Olyset)
Number of subjects: 1299

Group type: EXPERIMENTAL
Intervention: PPF-permethrin nets
Number of subjects: 1299

Group type: COMPARATOR
Intervention: PPF-permethrin nets and Standard LLINs
Number of subjects: 1299
Study: 29108096

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Substance Abuse-Domestic Violence (SADV)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Drug Counseling (DC)
Number of subjects: 63
Study: 27778458

Group type: EXPERIMENTAL
Intervention: 6x/wk hemodialysis
Number of subjects: 245

Group type: COMPARATOR
Intervention: 3x/wk hemodialysis
Number of subjects: 245
Study: 25185754

Group type: EXPERIMENTAL
Intervention: 6:1‐OM3 (4 g/day)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 6:1‐OM3 (4 g/day) in hypertriglyceridemic subjects
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo: corn oil
Number of subjects: 110
Study: 21550779

Group type: EXPERIMENTAL
Intervention: Resonance tube phonation for approximately 1 minute
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resonance tube phonation with instruction to keep pitch and loudness consistent
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resonance tube phonation with instruction to maximize ease of phonation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline measurements before tube phonation
Number of subjects: 20
Study: 18038188

Group type: COMPARATOR
Intervention: Didactic format (information first)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Problem format (case first)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Sensing learners
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Intermediate learners
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Intuitive learners
Number of subjects: 123

Group type: COMPARATOR
Intervention: Format preference
Number of subjects: 123

Group type: COMPARATOR
Intervention: Time to complete modules
Number of subjects: 123
Study: 17594926

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg once daily
Number of subjects: 96

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg once daily
Number of subjects: 96
Study: 16275811

Group type: EXPERIMENTAL
Intervention: Usual care plus a 15-session group cognitive therapy prevention program (n = 45)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Usual care (n = 49)
Number of subjects: 94
Study: 11790656

Group type: EXPERIMENTAL
Intervention: Hyperoxic test (HT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Alternate breath test (ABT)
Number of subjects: 18
Study: 9579452

Group type: EXPERIMENTAL
Intervention: 75 gm glucose load
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100 gm glucose load
Number of subjects: 60

Group type: COMPARATOR
Intervention: Capillary blood measurement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Venous plasma measurement
Number of subjects: 60
Study: 7537665

Group type: EXPERIMENTAL
Intervention: Metastron (Strontium-89)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2909288

Group type: EXPERIMENTAL
Intervention: Furosemide 20 mg/m2 1 hour before CDDP administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: No diuretic drug (Control)
Number of subjects: 20
Study: 1237234

Group type: EXPERIMENTAL
Intervention: Polyunsaturated diet for 20 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Saturated diet for 20 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Combined difference between saturated and polyunsaturated diets
Number of subjects: 25
Study: 31286728

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding (at specific acupoints), once every two weeks, six times as a course of treatment, until 12 weeks into pregnancy.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group treated with intramuscular injection of progesterone (40 mg) once every day.
Number of subjects: 60